India’s childhood cancer survivors will nearly triple by 2030, and most live far from care

When a child survives cancer, the victory is often celebrated and then quietly forgotten by the health system. But the survivors keep growing up, and they carry with them the biological consequences of the treatments that saved them. A new multi-centre analysis from North India, published in Frontiers in Adolescent Medicine, has for the first time quantified exactly how many childhood cancer survivors in the region are approaching the vulnerable moment when they must leave pediatric oncology behind and enter adult-oriented care. The numbers are stark: of 3,060 survivors who completed therapy between 2016 and 2025 across three tertiary pediatric oncology centres, 398, or 13 percent, had already passed their eighteenth birthday by December 2025 and were eligible for transition. By 2030, that figure is projected to swell to 1,071, a cumulative increase of 169.1 percent in just five years.

The arithmetic behind this surge is unforgiving and, the authors argue, structural rather than institutional. Cure rates in pediatric oncology have improved steadily in India, as they have across other low- and middle-income countries. The cohorts treated during the 2016 to 2025 window are dominated by adolescents, and every successive calendar year delivers another group of teenagers across the adult threshold. The growth was consistent at all three participating centres despite very different case mixes and registration policies: the All India Institute of Medical Sciences in Delhi, coded C1, is projected to see a 253.9 percent increase by 2030; Rajiv Gandhi Cancer Institute and Research Centre, coded C2, a 115.3 percent increase; and King George’s Medical University in Lucknow, coded C3, a 248.8 percent increase. When the same pattern emerges at three institutions with different patient populations, the conclusion is that India is facing a nationwide survivorship demand of a scale that took European and North American consortia decades of dedicated infrastructure to serve.

What makes the projection genuinely alarming is not just the headcount but the acuity of the population being counted. Using published diagnosis- and exposure-based criteria, the researchers classified each survivor by their risk of developing treatment-related late effects. Only 11 survivors, 2.7 percent, were low risk. The remaining 387, or 97.2 percent, were classified as either moderate risk, 44.9 percent, or high risk, 52.3 percent. These are not survivors who can be discharged to routine primary care with reassurance. The predominant diagnoses were lymphoma at 34.1 percent, solid tumors at 29.1 percent, and acute lymphoblastic leukemia at 27.8 percent, diagnostic groups carrying well-documented risks from anthracycline chemotherapy, alkylating agents, radiation exposure, and site-specific surgical late effects that may manifest decades after treatment ends.

The biology of these late effects is precisely why risk-stratified surveillance matters. Anthracyclines, among the most effective drugs in pediatric oncology, carry cumulative risks of cardiomyopathy that can surface silently in early adulthood. Alkylating agents impair fertility and raise the risk of subsequent malignancies. Radiation to the chest, brain, or endocrine axes sets the stage for secondary cancers, cognitive deficits, growth hormone deficiency, and metabolic syndrome. The Children’s Oncology Group long-term follow-up guidelines, harmonized internationally, prescribe exposure-based screening schedules for exactly these reasons. A cohort that is 97 percent moderate or high risk requires structured, specialist-informed surveillance, not a farewell handshake at the pediatric clinic door.

Yet the geography of the Indian survivor population makes hub-based follow-up unrealistic for most. Uttar Pradesh contributed the largest share of transition-eligible survivors, 142 of 398, or 35.7 percent, followed by Delhi NCR at 20.1 percent, Haryana at 9.5 percent, and Bihar at 8.5 percent. Remarkably, 27 survivors, 6.8 percent, reside in Nepal, confirming that these tertiary centres function as national and cross-border referral hubs. The distance analysis made the dispersion concrete: only 42 percent of survivors with mappable addresses live within 50 kilometers of their treating institution, while 27.4 percent live more than 100 kilometers away, 18.3 percent beyond 200 kilometers, and a further group outside the country altogether. Roughly 58 percent of the cohort resides more than 50 kilometers from the centre that treated them.

Distance is not a soft barrier. International literature consistently identifies travel burden, cost, and time away from work as principal determinants of long-term follow-up attendance, and Asian surveys of providers cite geography, transportation, and competing priorities as dominant obstacles to survivorship participation. The Indian survey embedded in this study, completed by 25 of 30 eligible pediatric oncology centres for an 83.3 percent institutional response rate, found that geographic distance was endorsed as a barrier by 56 percent of centres, behind only lack of perceived need at 78 percent and lack of awareness about late effects at 67 percent. These three barriers compound one another in a devastating way: a survivor who feels well, has never been told what to watch for, and lives 200 kilometers from the clinic has no reason to make the journey. This is the mechanism behind the 22 percent loss to follow-up reported from a large Indian institutional cohort, and the authors are explicit that it will not be solved by expanding clinic capacity at the hub.

The survey also exposed how little transition infrastructure exists. At 56 percent of centres, the transition process was non-existent; at another 33 percent, it was informal and ad hoc. No centre used a defined transition age, and survivors typically stopped attending once they judged themselves cured, even though 66 percent of centres did generate end-of-treatment summaries containing diagnosis and treatment exposures. Once survivors attain transition age, they either continue follow-up indefinitely in pediatric survivorship clinics or are simply lost to the system. The median interval from treatment completion to transition was 3.9 years overall, but it varied dramatically between centres, from 2.1 years at C2 to 7.3 years at C1, reflecting differences in the upper age limit for pediatric oncology registration rather than any difference in biology or outcome. The authors argue this inconsistency is itself an argument for a nationally agreed definition of transition age.

The framework the researchers propose treats risk stratum and geographic distance as two axes of a single allocation decision rather than separate considerations. Low- and moderate-risk survivors living within reach of a district or secondary facility can reasonably be followed there under shared-care arrangements anchored by a portable treatment summary and an exposure-based surveillance schedule, with the tertiary hub reachable by teleconsultation. High-risk survivors living close to a hub should retain hub-based, risk-based adult follow-up of the kind long advocated in high-income systems. The genuinely difficult quadrant, high-risk survivors living far from any hub, which in this cohort is a substantial group, requires an explicit networked solution: designated spoke centres with a named contact, scheduled tele-survivorship reviews, locally available surveillance investigations, and hub review at defined intervals rather than on demand.

Three enablers make this model feasible with existing resources. The treatment summary, already produced by two-thirds of surveyed centres, should become the transferable instrument of care rather than a discharge formality, issued to the survivor as well as to the receiving clinician. A named transition coordinator drawn from existing staff would provide the structural accountability whose absence is the commonest reason transition fails internationally, and the authors argue that full-time, independent personnel are essential given the projected growth in survivor numbers and the intensity of risk-based surveillance and patient education required. Transfer itself should be triggered by an assessment of readiness, including health literacy, autonomy, pubertal and growth status, and psychological preparedness, rather than by a birthday alone, which would also resolve the inter-centre inconsistency the data exposed. The existing Indian Childhood Cancer Survivorship registry, which already links more than 5,400 survivors across 20 centres on a common database, could plausibly host risk stratum, surveillance schedule, and transition status as registry fields, converting a research cohort into an operational recall system.

The authors are careful to acknowledge the limitations of their analysis. It is a synthesis of institutional cohort data from three centres in North India, not a population-based estimate, and the projections assume stable treatment volumes, survival, and registration policy. Geographic coding relied on the most recent documented residential address, which may be outdated and permitted only state- and district-level resolution. Risk classification was applied to available treatment-exposure data and did not capture complications encountered during therapy. The survey reflects the perceptions of centres with existing survivorship clinics, which probably overstates the readiness of the wider system, and it lacks the patient’s voice. The study quantified those who become eligible for transition, not those who actually transitioned, and did not measure outcomes after transfer. Even so, the estimate is likely conservative: it is restricted to three centres in one region of a country that treats childhood cancer across several hundred units, anchored to a ten-year treatment window that excludes survivors treated before 2016 who are already adults. The window to build a risk-stratified, geographically distributed survivorship architecture, the authors conclude, is open now, while the cohort is still counted in hundreds rather than thousands.

Subject of Research: Estimates of transition burden, geographic distribution, and risk-stratified care for adolescent and young adult cancer survivors: A multi-centre analysis from a low- and middle-income country

Article Title: Estimates of transition burden, geographic distribution, and risk-stratified care for adolescent and young adult cancer survivors: A multi-centre analysis from a low- and middle-income country

Article References: Estimates of transition burden, geographic distribution, and risk-stratified care for adolescent and young adult cancer survivors: A multi-centre analysis from a low- and middle-income country. (n.d.). https://doi.org/10.3389/fradm.2026.1982235

Image Credits: AI Generated

DOI: 10.3389/fradm.2026.1982235

Keywords: adolescent and young adult oncology, childhood cancer survivors, cancer survivorship, transition of care, India, late effects, health systems, Estimates, transition, burden, geographic, distribution